Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GRT-R912 (Gritstone bio, Inc.)
- Development stage
- Unknown
- Lead developer
- Gritstone Oncology
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
GRT-R912 is a self-amplifying mRNA (samRNA) vaccine candidate developed by Gritstone bio as part of its CORAL program for the prevention of COVID-19. Unlike conventional mRNA vaccines, samRNA is designed to replicate once inside the cell, potentially allowing for lower doses and more durable immune responses. GRT-R912 specifically targets the SARS-CoV-2 Spike protein (Beta variant) along with a proprietary set of highly conserved T-cell epitopes (TCE11) to drive both broad B-cell and robust T-cell immunity. It is currently being evaluated in Phase 1 clinical trials to assess safety, tolerability, and immunogenicity in various populations, including healthy adults and people living with HIV.
- Other names
- samRNA-Spikebeta-TCE11samRNA-Spikebeta-TCE-11samRNA-Spikebeta-TCE 11
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on GRT-R912 (Gritstone bio, Inc.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GRT-R912 (Gritstone bio, Inc.).